EnWave Signs Material Transfer Agreement with AstraZeneca to Trial Radiant Energy Vacuum Technology for Pharmaceutical Dehydr...
July 09 2021 - 9:00AM
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the
“Company”) announces that it has signed a material
transfer agreement (“MTA”) with MedImmune Limited, an affiliate of
AstraZeneca AB (LSE/STO/Nasdaq: AZN) (“AZ”), to facilitate the
trialing of EnWave’s Radiant Energy Vacuum (“REV”) technology for
the dehydration of liquid monoclonal antibody formulations. AZ will
send proprietary materials to EnWave’s testing facility in
Vancouver, Canada to conduct initial proof-of-concept trials. If
successful, the two companies intend to negotiate a more robust
agreement to allow for further research and development activities.
About AstraZeneca ABAstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development and
commercialization of prescription medicines in Oncology and
BioPharmaceuticals, including Cardiovascular, Renal &
Metabolism, and Respiratory & Immunology. Based
in Cambridge, UK, AstraZeneca operates in over 100 countries,
and its innovative medicines are used by millions of patients
worldwide.
More information about AstraZeneca is available
at www.astrazeneca.com.
About EnWave EnWave
Corporation, a Vancouver-based advanced technology company, has
developed a Radiant Energy Vacuum (“REV™”) – an innovative,
proprietary method for the precise dehydration of organic
materials. EnWave has further developed patent-pending methods for
uniformly drying and decontaminating cannabis through the use of
REV™ technology, shortening the time from harvest to high-quality,
marketable cannabis products.
REV™ technology’s commercial viability has been
demonstrated and is growing rapidly across several market verticals
in the food, and pharmaceutical sectors, including legal cannabis.
EnWave’s strategy is to sign royalty-bearing commercial licenses
with innovative, disruptive companies in multiple verticals for the
use of REV™ technology. The company has signed over forty
royalty-bearing licenses to date in twenty countries world-wide. In
addition to these licenses, EnWave established a Limited Liability
Corporation, NutraDried Food Company, LLC, to manufacture, market
and sell all-natural dairy snack products in the United States,
including the Moon Cheese® brand.
EnWave has introduced REV™ as a disruptive
dehydration platform in the food and cannabis sectors: faster and
cheaper than freeze drying, with better end product quality than
air drying or spray drying. EnWave currently offers two distinct
commercial REV™ platforms:
- nutraREV® which is a drum-based system that dehydrates organic
materials quickly and at low-cost, while maintaining high levels of
nutrition, taste, texture and colour; and,
- quantaREV® which is a tray-based system used for continuous,
high-volume low-temperature drying.
More information about EnWave is available at
www.enwave.net.
EnWave CorporationMr. Brent
Charleton, CFAPresident and CEO
For further information:
Brent Charleton, CFA, President and CEO at +1 (778)
378-9616E-mail: bcharleton@enwave.netDan Henriques, CPA, CA, CFO at
+1 (604) 835-5212E-mail: dhenriques@enwave.net
For Media Inquiries:E-mail: media@enwave.net
Safe Harbour for Forward-Looking Information
Statements: This press release may contain forward-looking
information based on management's expectations, estimates and
projections. All statements that address expectations or
projections about the future, including statements about the
Company's strategy for growth, product development, market
position, expected expenditures, and the expected synergies
following the closing, are forward-looking statements. All
third-party claims referred to in this release are not guaranteed
to be accurate. All third-party references to market information in
this release are not guaranteed to be accurate as the Company did
not conduct the original primary research. These statements are not
a guarantee of future performance and involve a number of risks,
uncertainties and assumptions. Although the Company has attempted
to identify important factors that could cause actual results to
differ materially, there may be other factors that cause results
not to be as anticipated, estimated or intended. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accept responsibility for the
adequacy or accuracy of this release.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024